Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. (NBIX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
nbix · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Neurocrine Biosciences, Inc. (NBIX) measures how much investors pay for each dollar of the company's trailing earnings. NBIX's current PE ratio of 24.49x is calculated by dividing its stock price of $163.44 by its TTM earnings per share of $6.65. −57.1% discount vs 5Y avg 57.0x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 10 fiscal years · Front-end computedMinQ1 · 25%62.8x
MedianQ3 · 75%322.7x
Max
At 24.49x, NBIX's current P/E is lower than in 20% of its annual fiscal year readings over the past 10 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Neurocrine Biosciences, Inc.You NBIX | $16.4B | 24.49x | -34.9% | $6.65 |
 The Cooper Companies, Inc. COO | $13.2B | 37.30x | -0.9% | $1.87 |
 Elanco Animal Health Incorporated ELAN | $11.6B | N/A | — | -$0.47 |
 Hologic, Inc. HOLX | $17.0B | 26.99x | -28.3% | $2.49 |
 ICON Public Limited Company ICLR | $11.7B | 62.31x | +65.6% | $2.92 |
 Dr. Reddy's Laboratories Limited RDY | $11.1B | 23.89x | -36.5% | $54.16 |
 Summit Therapeutics Inc. SMMT | $11.2B | N/A | — | -$1.44 |
Industry Average 4 peers with valid PE | — | 37.62x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 29.49x | $4.81 | -26.6% | |
2024-12-31 FY2024 | 40.15x | $3.40 | -22.1% | |
2023-12-31 FY2023 | 51.55x | $2.56 | -30.4% | |
2022-12-31 FY2022 | 74.06x | $1.61 | -17.6% | |
2021-12-31 FY2021 | 89.92x | $0.95 | +310.4% | |
2020-12-31 FY2020 | 21.91x | $4.37 | -91.8% | |
2019-12-31 FY2019 | 266.19x | $0.40 | -17.5% | |
2018-12-31 FY2018 | 322.70x | $0.22 | — | |
2017-12-31 FY2017 | — | $-1.62 | — | |
2016-12-31 FY2016 | — | $-1.63 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Neurocrine Biosciences, Inc. (NBIX) measures how much investors pay for each dollar of the company's trailing earnings. NBIX's current PE ratio of 24.49x is calculated by dividing its stock price of $163.44 by its TTM earnings per share of $6.65.
Frequently asked questions
NBIX pe ratio · 6 questionsNBIX's current PE ratio is 24.49x as of 2026-06-08, based on a stock price of $163.44 and TTM EPS of $6.65. Data sourced from Financial Modeling Prep via NBIX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Neurocrine Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08